Crinetics (CRNX) announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The Phase 3 study builds on Phase 2 data in which paltusotine demonstrated rapid and sustained reductions in the frequency and severity of carcinoid syndrome symptoms, including flushing episodes and bowel movements.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals
- Crinetics price target raised to $45 from $40 at Goldman Sachs
- Crinetics Pharma’s Positive Earnings Call Highlights PALSONIFY Success
- Crinetics Pharmaceuticals: Strong Market Entry and Financial Position Support Buy Rating
- Crinetics price target lowered to $108 from $143 at Citizens JMP